Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis

Marlies Wijsenbeek*, Jeffrey J. Swigris, Yoshikazu Inoue, Michael Kreuter, Toby M. Maher, Takafumi Suda, Michael Baldwin, Heiko Mueller, INBUILD Trial Investigators, Klaus B. Rohr, Kevin R. Flaherty

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
6 Downloads (Pure)

Abstract

BACKGROUND: 

Dyspnoea and cough can have a profound impact on the lives of patients with pulmonary fibrosis. We investigated the effects of nintedanib on the symptoms and impact of pulmonary fibrosis in patients with progressive pulmonary fibrosis (PPF) in the INBUILD trial using the Living with Pulmonary Fibrosis (L-PF) questionnaire. 

METHODS: 

Patients had a fibrosing interstitial lung disease (ILD) (other than idiopathic pulmonary fibrosis) of >10% extent on high-resolution computed tomography (HRCT) and met criteria for ILD progression within the prior 24 months. Patients were randomised 1:1 to receive nintedanib or placebo. Changes in L-PF questionnaire scores from baseline to week 52 were assessed using mixed models for repeated measures. 

RESULTS:

In total, 663 patients were treated. Compared with placebo, there were significantly smaller increases (worsenings) in adjusted mean L-PF questionnaire total (0.5 versus 5.1), symptoms (1.3 versus 5.3), dyspnoea (4.3 versus 7.8) and fatigue (0.7 versus 4.0) scores in the nintedanib group at week 52. L-PF questionnaire cough score decreased in the nintedanib group and increased in the placebo group (-1.8 versus 4.3). L-PF questionnaire impacts score decreased slightly in the nintedanib group and increased in the placebo group (-0.2 versus 4.6). Similar findings were observed in patients with a usual interstitial pneumonia-like fibrotic pattern on HRCT and in patients with other fibrotic patterns on HRCT.

CONCLUSION: 

Based on changes in L-PF questionnaire scores, nintedanib reduced worsening of dyspnoea, fatigue and cough and the impacts of ILD over 52 weeks in patients with PPF.

Original languageEnglish
Article number2300752
JournalThe European respiratory journal
Volume63
Issue number2
DOIs
Publication statusPublished - 1 Feb 2024

Bibliographical note

Publisher Copyright:
Copyright ©The authors 2024.

Fingerprint

Dive into the research topics of 'Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis'. Together they form a unique fingerprint.

Cite this